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Histidine-tryptophan-ketoglutarate (HTK) is replacing
University of Wisconsin (UW) solution as the preser-
vation fluid for renal allografts in many centers, but
recent large-scale data to support this transition are
lacking. We conducted a retrospective analysis of pa-
tient and graft outcomes after renal transplantation
at our center, comparing 475 consecutive living donor
and 317 deceased donor transplants since the adoption
of HTK with equal numbers of grafts preserved using
UW solution. Data collected included donor and recip-
ient age, race, sex, comorbidities and graft ischemia
time. Graft and patient survival, as well as the inci-
dence of delayed graft function (DGF), were studied
by Kaplan–Meier and Cox regression analysis. No sig-
nificant difference was seen in either patient or graft
survival. Deceased donor kidneys in the HTK group
had a higher incidence of DGF than the UW cohort,
whereas this trend was reversed in the case of living
donor organs. In multivariate analysis, HTK was asso-
ciated with a significant risk reduction on the incidence
of DGF. Prolonged preservation with HTK compared to
UW was not associated with excess risk to the graft or
patient. In summary, HTK demonstrated efficacy simi-
lar to UW in terms of patient and graft survival.
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Introduction
Histidine-tryptophan-ketoglutarate (HTK) solution was in-
troduced in the 1970s as a cardioplegic agent, and was
initially described as an allograft storage solution in 1984.
In recent years, HTK has replaced University of Wisconsin
(UW) solution as the standard organ preservation fluid at
many centers. The purported advantages of HTK include
lower viscosity and improved organ flushing characteris-
tics, better cell preservation over a wide range of tempera-
tures and increased clearance of residual donor blood from
the microvasculature (1,2). Anecdotal evidence also sug-
gests decreased potential for causing bradyarrhthymias af-
ter reperfusion of the renal allograft when compared to
UW, though in practice this is a rare and largely preventable
occurrence with either solution (3–5). HTK is also consider-
ably less expensive to use than UW, despite the need for
higher volumes of fluid per donor recovery (6).
Although HTK is now widely used, many continue to ques-
tion its suitability as a kidney preservation agent. Cell cul-
ture and small animal models have shown unfavorable
changes in cell morphology, caspase activation and other
markers of tissue injury in HTK-preserved samples (7,8).
Clinical studies have not demonstrated significant differ-
ences between HTK and UW in deceased donor kidneys
(9,10), but recent, large-scale data with follow-up of both
deceased donor and living-donor grafts are lacking. Out-
comes from organs with prolonged ischemic time are of
particular interest, as it is in these cases that HTK is posited
to provide suboptimal preservation (11).
Our center adopted HTK for living donor transplants in
2002, and for deceased donor transplants beginning in
2003. In this report, we present data from our center re-
garding 475 living and 317 deceased donor organs pre-
served with HTK. We compared patient and graft survival
rates from these operations with those of the latest UW-
preserved grafts at our center, dating back to 1997. We
also studied rates of technical graft loss and delayed graft
function, as well as outcomes with organs that underwent
prolonged cold ischemia. Our hypothesis was that preser-
vation with HTK and the UW solution would be comparable
for both deceased and living donor kidney transplants.
Methods
Patients
Approval for data collection and analysis was obtained from the University
of Michigan Institutional Review Board. All living donor renal allografts at
the University of Michigan were preserved with HTK solution beginning
in October 2002, and all deceased donor kidneys recovered within Region
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10 were preserved with HTK solution beginning in December 2003. All
adult kidney-only transplant procedures utilizing HTK were retrospectively
reviewed, totaling 475 living and 317 deceased donor organs. Historical
controls were obtained by using equal numbers of the most recent adult
patients who received kidney transplants that had been preserved using
UW solution, dating back to 1997 for living donors and 1999 for deceased
donors. Data were obtained from the University of Michigan online trans-
plant information database and patient care systems, including recipient
age, gender, race, underlying cause of renal failure, transplant date, cold
and warm ischemia time, lost to follow-up date, date of death, date of graft
loss and ALL Patient Refined Diagnosis-Related Group (APR-DRG) severity
score. The APR-DRG is a measure of complexity of care for given condi-
tions, and can be used to convey severity of illness and risk of mortality
across a diagnosis group. In common practice, APR-DRG weights reflect
the amount of resources required to care for patients with the same dis-
ease or operation. Delayed graft function was defined as requirement for
dialysis in the first 7 days after transplant. Donor characteristics included
age, gender and donor type.
Statistical analysis
The student’s t-test was utilized to compare continuous variables, and the
chi-square test used to determine differences in categorical variables. The
primary outcome measures included time-dependent patient and graft sur-
vival. The primary exposure variable was the type of preservation solution
(HTK solution vs. UW.) Patient and graft survival were compared using
Kaplan–Meier survival analysis, stratifying for living donors and deceased
donors. Cox proportional regression models were created to determine in-
dependent covariates (donor, recipient and preservation) that affected pa-
tient and graft survival. This method also allowed evaluation of interaction
effects between the preservative type, cold-ischemia time and donor type.
Rates of technical graft loss, defined as graft loss within 2 weeks of the
kidney transplant operation without evidence of rejection, were computed
for each fluid and donor type. SPSS V15.0 (Chicago, IL) was used for data
analysis.
Table 1: Recipient and donor demographics
Preservative
Deceased donors
Variable UW (n = 317) HTK (n = 317) p-Value
Male sex 57% 62% 0.13
Caucasian 77% 67% < 0.01∗
Diabetes 29% 36% 0.08
Age at transplant (yrs) 48.6 ± 13.0 50.8 ± 12.2 0.02∗
Donor age (yrs) 35.0 ± 15.7 38.0 ± 15.3 0.02∗
Cold ischemia time (min) 949.6 ± 423.2 877.0 ± 541.4 0.08
Total ischemia time (min) 991.4 ± 421.2 912.5 ± 540.6.2 0.06
Total ischemia time >24 h 10.6% 9.5% 0.60
APRDRG weight 5.8 ± 1.3 6.1 ± 1.8 0.048∗
Preservative
Living donors
Variable UW (n = 475) HTK (n = 475) p-Value
Male sex 54% 62% 0.01∗
Caucasian 84% 83% 0.36
Diabetes 33% 33% 0.53
Age at transplant (yrs) 43.8 ± 13.4 47.8 ± 13.4 < 0.01∗
Donor age (yrs) 39.9 ± 11.4 40.4 ± 10.7 0.43
Cold ischemia time (min) 87.3 ± 68.0 117.8 ± 118.7 < 0.01∗
Total ischemia time (min) 120.2 ± 69.8 152.1 ± 119.5 0.31
Total ischemia time >24 h 0.0% 0.1% 0.47
APRDRG weight 5.4 ± 0.90 5.5 ± 0.93 0.36
∗ P < 0.05.
Results
Demographic data on living and deceased donor organs are
summarized in Table 1. Among the deceased donor recip-
ients, the HTK group had a higher percentage of African
Americans than did the UW patients. Kidneys preserved
with HTK were recovered from significantly older donors
and transplanted into older recipients when compared to
the UW control group. Similarly, among the living donor
recipients, in comparison to the UW-preserved group, the
HTK group of living-donor organ recipients was older and
had a higher proportion of males. In addition, cold ischemia
time in the HTK recipients was longer (117 vs. 87.3 min,
p < 0.01). APRDRG weight was comparable between the
living donor groups. Finally, the deceased donor HTK recip-
ients’ APRDRG weight tended toward the higher end of
the scale than that of the UW sample (Figure 1).
Kaplan–Meier analysis demonstrated no difference in pa-
tient survival between HTK and UW preservation solu-
tions, in either the living-donor or deceased donor groups
(Figure 2). Patient survival at 50 months was over 80% in
the deceased donor patients and over 90% in the living-
donor patients. Graft survival did not significantly differ
by preservation solution, but in living-donor patients; HTK
showed a trend toward improved long-term graft survival
over UW solution (Figure 3). Cox regression modeling
demonstrated patient survival to be independently pre-
dicted by a younger recipient age at transplantation, the
absence of diabetes and receiving a living donor compared
to a deceased donor kidney (Table 2, part A). Our baseline
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Figure 1: Distribution of APRDRG
severity scores (composite index
of comorbidities and acute illness
severity) among recipients of liv-
ing and deceased donor kidney al-
lografts, by preservative solution
type.
case was a female Caucasian without diabetes who re-
ceived a kidney from a living donor preserved with UW
solution with a cold ischemia time of less than 24 h. This
model noted no independent relationship between preser-
vation solution and patient survival. Organs with a cold is-
chemia time of more than 24 h did not significantly impact
survival. Interaction modeling to assess the cumulative im-
pact of choice of preservative fluid with allograft type and
prolonged ischemia time did not demonstrate a significant
effect on patient survival. In a model limited to recipients
of living donor grafts, advanced recipient age and diabetes
imparted a significant risk of death, but preservation fluid
did not affect survival (Table 2, part B). The deceased donor
model was most heavily impacted by recipient age, with
additional dependence on donor age. Again, preservation
fluid did not reach statistical significance for patient sur-
vival.
Graft survival was defined as independence from dialysis,
or by loss of function in grafts of patients not yet requiring
dialysis. Modeling by Cox regression showed a 45% higher
risk of graft loss with deceased donor than with living donor
kidneys (Table 3, part A). Delayed graft function imparted
a large and statistically significant risk to long-term graft
survival. Use of UW or HTK did not change risk of graft loss,
nor did prolonged cold-ischemia time. Interaction variables
combining preservation fluid, extended cold-ischemia, and
donor type were not significant predictors of graft loss,
and analyses were of insufficient power to include in the
model. Discrete analysis of deceased donors showed an
increased risk with organs from older donors, while none
of the variables in a living-donor model reached statistical
significance (Table 3, part B).
Analysis of rates of technical graft loss was limited by its
low overall incidence of 0.44%. Cox modeling did not iso-
late predictive factors for organ loss within 14 days of trans-
plantation, and rates in the UW and HTK groups were com-
parable across donor type (Table 4). Data on delayed graft
function are also shown in Table 4. Deceased donor kid-
neys in the HTK group had a higher incidence of DGF that
those in the UW cohort, whereas this trend was reversed
in the case of living donor organs. In multivariate analy-
sis, HTK organ preservation was associated with a 70%
reduction in risk for DGF, as shown in Table 5. Other sig-
nificant factors in the DGF model included race other than
Caucasian, advanced donor age, deceased donor graft and
recipient diabetes. Cold ischemia time did not reach sig-
nificance in this model, and interaction variables were of
insufficient power to model reliably because of small sam-
ple size. The total number of deceased donor recipients
with DGF after prolonged (>24 h) ischemia was numeri-
cally similar between UW and HTK, with 9 patients in each
group having DGF and 25 and 24 patients having no DGF
under UW and HTK, respectively (p = NS).
Discussion
In this study, we conducted a retrospective analysis of graft
and patient survival in recipients of renal allografts pre-
served with either UW or HTK solution. Our data do not
show any statistically significant difference between the
two preservation fluids, though there was a trend toward
improved graft survival in the HTK living donor group. We
also studied whether choice of preservation fluid affected
rates of technical graft loss, and again found no significant
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Figure 2: Kaplan–Meier patient
survival after kidney transplant
using either UW or HTK organ
preservation solution. The hazard
ratio refers to the risk of patient
death when HTK solution was used
compared to UW solution.
differences attributable to graft storage solution. We did
note differences in DGF rates; the HTK cohort had a higher
incidence of DGF in deceased donor cases and a lower
incidence of DGF in living donor cases. In spite of these
differences in DGF rates, overall patient and graft survival
rates were comparable. Although there are limitations to
this analysis, our results suggest that there are no signifi-
cant short- or long-term clinically significant differences be-
tween UW solution and HTK in deceased donor and living
kidney transplantation.
Previous comparisons between UW and HTK in renal trans-
plantation have been limited by small sample size and rel-
atively short follow-up (10–12). The largest studies, from
Eurotransplant, took place in the early 1990s. In addition,
the great majority of papers relating to UW and HTK in
renal transplantation included only deceased donor organs
(9–13). Given the widespread use of HTK solution for organ
preservation in United States, important questions remain
regarding the use of HTK in living donor transplantation
and the implications of using HTK in cases of prolonged
cold ischemia times. In addition, no previous studies have
compared University Wisconsin solution and HTK solution
with respect to long-term graft function. Our data suggest
that the use of HTK solution for the preservation of both
living and deceased donor kidneys has a similar efficacy
when compared to UW. There was a numerically higher
graft survival for living donor kidneys preserved with HTK
when compared to UW, but this did not reach statistical
significance.
Within our organ procurement organization, the standard
donor operation includes a 5 L aortic flush with HTK, with
an additional 300 cc of HTK used for back-table perfusion.
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Figure 3: Kaplan–Meier kidney
allograft survival after transplant
using either UW or HTK organ
preservation solution. The hazard
ratio refers to the risk of graft
loss when HTK solution was used
compared to UW solution.
This is concordant with data reported from European stud-
ies, where 5–6 L was the average HTK perfusate volume
(9,14), but greater than in the Agarwal series, which used
an average flush of 3.4 L (12). It is notable that the manu-
facturer’s instructions for HTK initially involved a 10 L flush,
but now recommend 6–8 min of perfusion with no specific
volume advisory (15). To date, no data have been published
correlating outcome with flush volumes beyond titration to
clear effluent.
Our experience suggests that, with cold ischemic times
over 24 h, there is no detriment associated with HTK use.
This claim has been perhaps the most contentious in the
adoption of HTK over UW solution. Roels et al. found an
increase in delayed graft function from 18% to 24% with
UW, and from 26% to 50% with HTK, with ischemia times
>24 h (11). In contrast, later work by Agarwal et al. showed
a reduction from 56% DGF with UW to 16% with HTK (12).
These studies offered similarly conflicting results regard-
ing graft function at 12 to 18 months posttransplantation.
Donor and recipient demographics were comparable in all
three studies, but the Roels study, like our own, involved
recipient operations at one center, as opposed to follow-
ing outcomes for grafts transplanted at multiple centers.
Our graft survival rates are consistent with recent stud-
ies, and suggest equivalence between the two preserva-
tion solutions in the setting of prolonged ischemia (16,17).
Our data on delayed graft function are mixed. Despite a
numerically higher incidence of DGF in the HTK group,
Cox multivariable regression analysis shows a reduction in
DGF with HTK preservation. This may reflect an era effect,
as discussed below, where the HTK variable represents
not only preservation solution, but a reference to year of
operation.
The primary limitations of our analysis are its retrospective
design and the asynchronous nature of the UW and HTK
treatment groups. Perioperative and postoperative care of
transplant patients is dynamic, and it is not possible to
discount an era effect that may mask inequality between
preservation fluids. While this cannot be fully excluded as
a confounder, certain aspects of the data tend to make it
less likely. Table 1 shows that patients in the HTK groups
were older and tended toward a higher donor age, recipient
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Table 2: A Cox regression analysis of patient survival following
kidney transplantation at the University of Michigan
Effect Hazard ratio 95%CI p-Value
A. Overall predictors of patient mortality
Recipient age (risk per year) 1.042 1.028–1.057 <0.001∗
Deceased donor graft 1.808 1.197–2.724 0.005∗
Diabetes 1.517 1.089–2.113 0.014∗
Donor age (risk per year) 1.011 0.998–1.024 0.094
HTK organ preservation 1.416 0.765–2.618 0.268
Male sex 1.148 0.818–0.612 0.424
Delayed graft function 1.398 0.603–3.240 0.435
Non-Caucasian race 0.859 0.545–1.354 0.513






ischemia >24 h) and
(HTK solution)
1.908 0.206–17.54 0.569
B. Significant predictors of patient mortality, by donor type
Living donors
Recipient age (risk per
year)
1.035 1.017–1.053 < 0.001∗
Diabetes 1.810 1.162–2.820 < 0.001∗
HTK organ preservation 0.906 0.501–1.637 0.744
Deceased donors
Recipient age (risk per
year)
1.061 1.038–1.085 < 0.001∗
Donor age (risk per year) 1.018 1.002–1.035 0.029∗
HTK organ preservation 1.054 0.558–1.991 0.870
APR-DRG and prevalence of recipient diabetes. With out-
comes that indicate clinical equivalence between HTK and
UW, it would require a very large era effect related to
unmeasured patient care improvements to balance out
increased patient risk factors, and to mask a detriment
associated with HTK use. Strategies of postoperative im-
munosuppression and monitoring at the University of
Table 3: Graft survival following kidney transplantation at the Uni-
versity of Michigan: A Cox regression of graft survival
Effect Hazard ratio 95%CI p-Value
A. Overall predictors of graft loss
Delayed graft function 3.736 1.783–7.829 <0.001∗
Diabetes 1.550 1.008–2.384 0.046∗
Deceased donor graft 1.453 0.854–2.469 0.167
Donor age (risk per year) 1.009 0.993–1.025 0.259
Male sex 0.895 0.587–1.365 0.607
Non-Caucasian race 1.139 0.671–1.933 0.630
Cold ischemia time >24 h 1.298 0.385–4.374 0.674
HTK organ preservation 1.048 0.468–2.349 0.909
Recipient age (risk per year) 1.000 0.984–1.017 0.990
B. Independent predictors of graft loss, by donor type
Living donors
HTK organ preservation 0.700 0.445–1.102 0.124
Deceased donors
Donor age (risk per year) 1.030 1.007–1.052 0.009∗
HTK organ preservation 0.792 0.484–1.298 0.355
Table 4: Delayed graft function and technical graft failure in renal
allografts
Preservative
Effect UW (n = 317) HTK (n = 317) p-Value
Deceased donors
Delayed graft function 17.4% 26.2% 0.005∗
Technical graft failure 0% 0.9% 0.249
Preservative
Effect UW (n = 475) HTK (n = 475) p-Value
Living Donors
Delayed graft function 8.2% 3.2% 0.001∗
Technical graft failure 0.6% 0.2% 0.624
Michigan have largely stayed the same between 2003 and
2007, and so no such large effect is likely to exist. One
area where interpretation of the data is limited is with re-
gard to delayed graft function. In our series, the incidence
of DGF increased in the HTK group, but HTK use was inde-
pendently associated with a reduction in DGF risk.
A reasonable conclusion from our data is that while HTK
and UW may perform differently in cellular and small animal
models, they appear to be equivalent in terms of preserving
renal parenchyma in clinical transplantation. If any clinically
important effect were to exist, it might be most evident
in the immediate postoperative period or in patients with
prolonged cold ischemia. While our data show a higher rate
of delayed graft function in the HTK deceased donor, but
not living donor population, multivariate regression anal-
ysis demonstrates a large and statistically significant ad-
vantage to HTK over UW solution. Similarly, no difference
was found on regression analysis of graft survival based
on preservation fluid and cold ischemia time of more than
24 h. The data set is sensitive to donor factors such as
donor age, donor type and prolonged ischemia, as well as
to recipient age and diabetes, which have been previously
shown to predict technical graft loss (18).
In this report, we present data from our center that sup-
ports use of HTK as a graft preservation solution in renal
transplantation. Within the limits of retrospective analysis
with a historic control, HTK demonstrated efficacy similar
to UW in terms of patient and graft survival, and its lower
Table 5: A Cox regression analysis of delayed graft function in
renal transplant recipients at the University of Michigan
Effect Hazard ratio 95%CI p-Value
HTK organ preservation 0.295 0.143–0.607 0.001∗
Non-Caucasian race 1.917 1.281–2.867 0.002∗
Donor age (risk per year) 1.020 1.006–1.033 0.003∗
Deceased donor graft 2.232 1.219–4.086 0.009∗
Diabetes 1.589 1.090–2.315 0.016∗
Cold ischemia time >24 h 1.811 0.733–4.476 0.198
Recipient age (risk per year) 1.006 0.991–1.021 0.437
Male sex 0.871 0.602–1.261 0.464
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cost represents a financial advantage to our organ procure-
ment organization and our transplant center.
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